Edition:
United Kingdom

Marinus Pharmaceuticals Inc (MRNS.OQ)

MRNS.OQ on NASDAQ Stock Exchange Global Market

8.08USD
13 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$8.08
Open
--
Day's High
--
Day's Low
--
Volume
100
Avg. Vol
375,291
52-wk High
$8.89
52-wk Low
$0.82

Latest Key Developments (Source: Significant Developments)

Marinus Pharmaceuticals files for mixed shelf of up to $200 mln
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Marinus Pharmaceuticals Inc :Marinus Pharmaceuticals Inc - files for a mixed shelf of up to $200 million - SEC filing‍​.  Full Article

Marinus Pharmaceuticals qtrly loss per share $0.15‍​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Marinus Pharmaceuticals Inc :Marinus Pharmaceuticals provides business update and reports third quarter 2017 financial results.Marinus Pharmaceuticals Inc - ‍"believes" cash, cash equivalents and investments as of Sept 30, 2017 are adequate to fund operations into 2020​.Marinus Pharmaceuticals Inc qtrly loss per share $0.15‍​.Marinus-Initiating Phase 2 feasibility study with ganaxolone iv in patients with refractory status epilepticus, data expected in 2018‍​.  Full Article

Marinus Pharma net loss per share $0.46
Tuesday, 9 Aug 2016 

Marinus Pharmaceuticals Inc : Marinus pharmaceuticals provides business update and reports second quarter 2016 financial results .Qtrly net loss per share of common stock-basic and diluted $0.46.  Full Article

Sphera Global Healthcare Management LP reports 6 pct passive stake in Marinus Pharmaceuticals
Wednesday, 6 Jul 2016 

Marinus Pharmaceuticals Inc : Sphera Global Healthcare Management LP reports 6 pct passive stake in Marinus Pharmaceuticals as of June 28, 2016 - SEC Filing Source - http://bit.ly/29i2Nxy Further company coverage: [MRNS.O] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Marinus Pharmaceuticals says Ganaxolone did not meet primary endpoint
Monday, 13 Jun 2016 

Marinus Pharmaceuticals Inc : Ganaxolone did not meet primary endpoint . Ganaxolone was generally safe and well tolerated . Marinus plans to discontinue its program in adult focal onset seizures . Plans to focus its efforts on advancing ganaxolone in status epilepticus and pediatric orphan indications. . Most common adverse events (>5%) reported at greater rates than placebo were somnolence (23.5% versus 4.5%), dizziness and fatigue . Majority of adverse events were rated as mild in severity .Announces Top-Line results from phase 3 trial in adult focal onset seizures.  Full Article

UPDATE 3-Sage soars as postpartum depression drug moves closer to approval

* Shares zoom about 55 pct to all-time high (Adds details from conference call, analyst comments and background on disease space)